Printer Friendly

ISIS ANNOUNCES PHASE I CLINICAL TRIAL RESULTS ON ISIS 2105

 CARLSBAD, Calif., April 29 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) announced today that the Phase I safety data on its genital wart product, ISIS 2105, were being presented today at a major international conference in Venice, Italy. The paper was given by Mr. Stephen Hutcherson at the International Society for Antiviral Research and is the first scientific presentation of results from a completed clinical trial on an antisense oligonucleotide.
 Genital warts are caused by the human papillomavirus (HPV), the fastest spreading, sexually-transmitted disease of viral origin. Available treatments are non-specific and are based on surgical or chemical removal of the wart. Thus, recurrence rates of genital warts after treatment can be in excess of 50 percent due to remaining infection of untreated surrounding tissue.
 The Phase I trial described by Mr. Hutcherdon involved administration of either ISIS 2105 or a placebo to 90 normal volunteers in a double blinded protocol. Each volunteer received intradermal injections to the forearm of either ISIS 2105 or placebo. Importantly, there were no clinically significant side effects for any individual receiving ISIS 2105. The most common local reactions to ISIS 2105 included mild redness and swelling at the injection sites that occurred four to eight hours after the injection and usually resolved completely by the next day.
 "We are pleased with the safety profile of ISIS 2105," said Dr. Daniel L. Kisner, chief operating officer. "ISIS 2105 is the first oligonucleotide analog to enter broad Phase II testing, and the results from this Phase I safety provided the groundwork for the ongoing Phase II studies now in progress in the U.S."
 Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic products based on oligonucleotides. Isis has a broad oligonucleotide research program, has multiple compounds in preclinical development and its first oligonucleotide-based drug, ISIS 2105, is in Phase II clinical trials.
 -0- 4/29/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., of Isis Pharmaceuticals, Inc., 619-931-9200; or Anthony J. Russo, Ph.D., of Noonan Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:

AH-WB -- NY103 -- 2808 04/29/93 15:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:364
Previous Article:NWNL REPORTS RECORD NET INCOME BEFORE ACCOUNTING CHARGE
Next Article:FOXMEYER PLACES $198 MILLION OF SENIOR NOTES, RESTRUCTURES $330 MILLION BANK LOAN AGREEMENT
Topics:


Related Articles
ISIS COMPLETES NORMAL SUBJECT STUDY AND INITIATES TRIALS IN PATIENTS WITH ITS FIRST ANTISENSE DRUG
ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS
ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS
ISIS ANNOUNCES CLINICAL ACTIVITY OF ANTISENSE DRUG; PHASE I/II DATA IN CMV RETINITIS TO BE PRESENTED AT SCIENTIFIC CONFERENCE
ISIS PHARMACEUTICALS' INVESTIGATOR PRESENTS PHASE I/II CLINICAL DATA ON ISIS 2922 FOR CMV RETINITIS AT INTERNATIONAL AIDS CONFERENCE
ISIS PHARMACEUTICALS COMMENCES CLINICAL TRIALS FOR ANTISENSE DRUG TO INHIBIT ICAM-1
ISIS BEGINS PHASE III CLINICAL TRIALS OF ANTISENSE COMPOUND TO TREAT CMV RETINITIS IN PATIENTS WITH AIDS
NOVEL ANTI-HIV COMPOUND FROM ISIS PHARMACEUTICALS INHIBITS VIRAL REPLICATION IN VIVO
ISIS INITIATES PHASE II CLINICAL TRIALS OF ISIS 2302, AN ANTISENSE COMPOUND TO TREAT INFLAMMATORY DISEASES
ISIS ANNOUNCES RESULTS OF PILOT PHASE II CLINICAL TRIAL OF GENITAL WART COMPOUND AND DECISION NOT TO PURSUE FURTHER DEVELOPMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters